- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00559754
A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.
5 listopada 2014 zaktualizowane przez: Hoffmann-La Roche
An Open Label Study to Assess the Effect of a Combination of Avastin and Docetaxel and Sequential Chemotherapy on Pathological Response in Patients With Primary Operable HER2 Negative Breast Cancer
This single arm study will assess the efficacy and safety of a combination of Avastin and docetaxel following cyclophosphamide and doxorubicin, in patients with HER2 negative operable breast cancer.
Patients will receive 4 x 3 week cycles of chemotherapy with doxorubicin (60mg/m2 iv on day 1 of each cycle) and cyclophosphamide (600mg/m2 iv on day 1 of each cycle).
They will then receive 4 x 3 week cycles of docetaxel (75mg/m2 on day 1 of each cycle) in combination with Avastin (15mg/kg on day 1 of each cycle).
The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals.
Przegląd badań
Status
Zakończony
Warunki
Interwencja / Leczenie
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
72
Faza
- Faza 2
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
-
Cordoba, Hiszpania, 14004
-
Jaen, Hiszpania, 23007
-
Lerida, Hiszpania, 25198
-
Malaga, Hiszpania, 29010
-
Zaragoza, Hiszpania, 50009
-
-
Barcelona
-
Sabadell, Barcelona, Barcelona, Hiszpania, 08208
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Kobieta
Opis
Inclusion Criteria:
- female patients, >=18 years of age;
- primary HER2-negative operable breast cancer;
- tumor >2cm in size;
- ECOG performance status 0-1.
Exclusion Criteria:
- previous treatment for breast cancer;
- metastatic disease;
- current or recent (within 10 days of first dose of Avastin) use of aspirin (>325mg/day) or full-dose anticoagulants for therapeutic purposes;
- clinically significant cardiovascular disease.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: 1
|
Zgodnie z zaleceniami
15 mg/kg dożylnie w 1. dniu każdego 3-tygodniowego cyklu
75 mg/m2 dożylnie w 1. dniu każdego 3-tygodniowego cyklu
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of Participants With Pathological Complete Response (pCR)
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria: 1) the primary tumor was Grade 5 (no malignant cells identified at the location of the primary tumor (ductal carcinoma in situ may be present); 2) no involvement was identified in the lymph nodes; 3) the tumour size at evaluation of the surgical piece was 0 centimeters (cm); and 4) the pathological staging of the tumour from the surgical piece was pT0pN0pM0, the stage is not applicable (NA).
It will only be considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
|
After Week 24 (surgery)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of Participants With Objective Clinical Response
Ramy czasowe: Within 28 days of enrollment, Weeks 12 and 24
|
Overall clinical response is the best response obtained through physical examination and/or radiological tests after completion of chemotherapy cycles.
The percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) and was categorized as clinical response (CR+PR) or clinical benefit (CR+PR+ no change [NC]).
Per RECIST, CR was defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level.
PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of the longest diameter (LD) of all target lesions.
No unequivocal progression of non-target disease.
No new lesions.
Complete and partial responses must have been confirmed no less than 4 weeks after the criteria for response were first met.
|
Within 28 days of enrollment, Weeks 12 and 24
|
Percentage of Participants With Breast-Conserving Surgery
Ramy czasowe: Week 24
|
Breast-conserving surgery was defined as lumpectomy + lymphadenectomy (LA), segmentectomy + LA, quadrantectomy + LA, or other (including sentinal node extirpation tumorectomy).
|
Week 24
|
Percentage of Participants With pCR by Proliferation of Ki67
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
Biomarker Ki67 proliferation was defined as low (less than [<]15% ) and high (≥15%).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by Kisspeptin (KISS1) Amplification
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
KISS1 amplification was defined as 1 (aneuploid), 2 (normal), 4 (amplification), or NE (not evaluated).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by KISS1 Protein Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
KISS1 protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by Vascular Endothelial Growth Factor Receptor (VEGFR) Amplification
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
VEFGR amplification was defined as 1 (aneuploid), 2 (normal), 4 (amplification), or NE (not evaluated).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by VEGFR Protein Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
VEGFR protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by Hypoxia Inducible Factor (HIF) Protein Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
HIF protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by Endothelial Nitric Oxide Synthase (ENOS) Protein Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
ENOS protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by Angiotension Protein Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
Angiotensin protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by Vascular Endothelial Growth Factor (VEGF) Gene Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
VEGF gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by VEGFR Gene Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
VEGFR gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by Phosphorylated AKT (pAKT) Gene Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
pAKT gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by HIF Gene Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
HIF gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by Insulin-Like Growth Factor (IGF) Gene Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
IGF gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by ENOS Gene Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
ENOS gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by Phosphorylated MAP Kinase (pMAPK) Gene Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
pMAPK gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by Angiotensin II Receptor Type I (AGTR) Gene Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
AGTR gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by KISS1 Gene Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
KISS1 gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0).
|
After Week 24 (surgery)
|
Percentage of Participants With pCR by RKISS1 Gene Expression
Ramy czasowe: After Week 24 (surgery)
|
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment.
The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria.
It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
RKISS1 gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0).
|
After Week 24 (surgery)
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 grudnia 2007
Zakończenie podstawowe (Rzeczywisty)
1 września 2010
Ukończenie studiów (Rzeczywisty)
1 września 2010
Daty rejestracji na studia
Pierwszy przesłany
15 listopada 2007
Pierwszy przesłany, który spełnia kryteria kontroli jakości
15 listopada 2007
Pierwszy wysłany (Oszacować)
16 listopada 2007
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
10 listopada 2014
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
5 listopada 2014
Ostatnia weryfikacja
1 listopada 2014
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby skórne
- Nowotwory
- Nowotwory według lokalizacji
- Choroby piersi
- Nowotwory piersi
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwnowotworowe
- Modulatory tubuliny
- Środki antymitotyczne
- Modulatory mitozy
- Środki przeciwnowotworowe, immunologiczne
- Inhibitory angiogenezy
- Środki modulujące angiogenezę
- Substancje wzrostowe
- Inhibitory wzrostu
- Docetaksel
- Bewacyzumab
Inne numery identyfikacyjne badania
- ML20382
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Rak piersi
-
Emory UniversityNational Cancer Institute (NCI)WycofanePrognostyczny rak piersi IV stopnia AJCC v8 | Przerzutowy nowotwór złośliwy w mózgu | Przerzutowy rak piersi | Anatomiczny IV stopień raka piersi American Joint Committee on Cancer (AJCC) v8
-
Jonsson Comprehensive Cancer CenterZakończonyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterZakończonyBiochemicznie nawracający rak prostaty | Przerzutowy rak prostaty | Nowotwór złośliwy z przerzutami w kości | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.RekrutacyjnyNiedrobnokomórkowy rak płuc z przerzutami | Oporny na leczenie niedrobnokomórkowy rak płuc | Rak płuca w stadium IV American Joint Committee on Cancer (AJCC) v8 | Rak płuc w stadium IVA AJCC v8 | Rak płuc w stadium IVB AJCC v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)ZakończonyGruczolakorak gruczołu krokowego III stopnia AJCC v7 | Gruczolakorak gruczołu krokowego II stopnia AJCC v7 | Stopień I gruczolakoraka gruczołu krokowego American Joint Committee on Cancer (AJCC) v7Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterRekrutacyjnyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
NRG OncologyNational Cancer Institute (NCI)Aktywny, nie rekrutującyAnatomiczny rak piersi IV stadium AJCC v8 | Prognostyczny rak piersi IV stopnia AJCC v8 | Nowotwór złośliwy z przerzutami w kości | Przerzutowy nowotwór złośliwy w węzłach chłonnych | Przerzutowy nowotwór złośliwy w wątrobie | Przerzutowy rak piersi | Przerzutowy nowotwór złośliwy w płucach | Nowotwór... i inne warunkiStany Zjednoczone, Kanada, Arabia Saudyjska, Republika Korei
-
National Cancer Institute (NCI)ZakończonyOporny na leczenie złośliwy nowotwór lity | Nawracający złośliwy nowotwór lity | Przerzutowy złośliwy nowotwór lity | Nieoperacyjny lity nowotwór | Nawracający rak drobnokomórkowy płuca | Stopień IIIA Rak drobnokomórkowy płuca AJCC v7 | Etap IIIB Rak drobnokomórkowy płuca AJCC v7 | Rak drobnokomórkowy... i inne warunkiStany Zjednoczone
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWycofanePrzerzutowy rak nerkowokomórkowy | Rak nerkowokomórkowy IV stopnia AJCC v8 | Rak brodawkowaty nerki | Zbieranie raka przewodów | Nieoperacyjny rak nerki | Dziedziczna leiomyomatoza i rak nerkowokomórkowy | Jasnokomórkowy brodawkowaty nowotwór nerki | Dziedziczny rak brodawkowaty nerki | Niesklasyfikowany... i inne warunkiStany Zjednoczone
-
Jonsson Comprehensive Cancer CenterAstraZenecaZakończonyRak płaskonabłonkowy jamy ustnej i gardła | Stopień kliniczny III zależny od HPV (p16-dodatni) rak jamy ustnej i gardła AJCC v8 | Stopień kliniczny II, w którym pośredniczy HPV (p16-dodatni) rak jamy ustnej i gardła AJCC v8 | Patologiczny etap I, w którym pośredniczy HPV (p16-dodatni) rak jamy... i inne warunkiStany Zjednoczone
Badania kliniczne na Standardowa chemioterapia
-
brett rasmussenZakończonyZapalenie powięzi podeszwowejStany Zjednoczone
-
Johns Hopkins UniversityRekrutacyjnyZespół przedziału nogi | Powikłania pozaustrojowego natlenienia błony | Niedokrwienie kończyny, stan krytyczny | Niedokrwienie kończynyStany Zjednoczone
-
Ziv HospitalJeszcze nie rekrutacja
-
Aventusoft, LLC.National Heart, Lung, and Blood Institute (NHLBI); Cleveland Clinic FloridaRekrutacyjnyNiewydolność serca (HF)Stany Zjednoczone
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsZakończonyCiężki COVID-19Izrael
-
Institut Claudius RegaudZakończonyRAK Z PRZErzutamiFrancja
-
Dana-Farber Cancer InstituteRekrutacyjnyChłoniak T-komórkowy skóry | Chłoniak z obwodowych komórek TStany Zjednoczone
-
Hofseth Biocare ASAKGK Science Inc.ZakończonyCovid-19 | COVIDKanada, Brazylia, Węgry, Meksyk, Serbia
-
City University of New York, School of Public HealthNew York State Psychiatric Institute; University of KwaZulu; International Initiative... i inni współpracownicyZakończony
-
Université de MontréalRekrutacyjnyZapalenie stawów barkuKanada